Effects of follicular output rate on cumulative clinical pregnancy rate and cumulative live birth rate in PCOS patients with different characteristics.

PCOS characteristics cumulative clinical pregnancy rate cumulative live birth rate follicular output rate in vitro fertilization-embryo transfer polycystic ovarian syndrome

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 25 10 2022
accepted: 06 12 2022
entrez: 5 1 2023
pubmed: 6 1 2023
medline: 7 1 2023
Statut: epublish

Résumé

We aim to explore the effects of follicular output rate (FORT) on cumulative clinical pregnancy rate (CCPR) and cumulative live birth rate (CLBR) in polycystic ovary syndrome (PCOS) patients with different characteristics undergoing This retrospective study analyzed 454 patients with PCOS undergoing their first IVF cycle at our center from January 2016 to December 2020. FORT was calculated as pre-ovulatory follicle count (PFC) × 100/antral follicle count (AFC). Multivariate regression analyses were conducted to explore the relationships between FORT and CCPR and CLBR. Curve fitting and threshold effect analyses were established to find nonlinear relationships. Effect modification in different subgroups were examined by stratification analyses. Based on the FORT values, individuals were classified into the following three groups: low-FORT group, middle-FORT group and high-FORT group. Multivariate regression analyses revealed that FORT was an independent factor affecting the CCPR and CLBR significantly (OR = 1.015, 95% CI: 1.001, 1.030 and OR = 1.010, 95% CI:1.001, 1.020). Curve fitting and threshold effect analyses showed that the CCPR and CLBR had a positive correlation with FORT when the FORT was less than 70% (OR = 1.039, 95% CI: 1.013, 1.065 and OR = 1.024, 95% CI: 1.004, 1.044). Stratification analyses showed that the CLBR increased by 1.3% with each additional unit of FORT for patients with hyperandrogenic manifestations (OR = 1.013, 95% CI: 1.001, 1.025). Compared with the low-FORT group, in the high-FORT group, CCPR increased 1.251 times for patients with polycystic ovarian morphology, while CCPR and CLBR increased 1.891 times and 0.99 times for those with ovulation disorder, respectively (OR = 2.251, 95% CI: 1.008, 5.028 and OR = 2.891, 95% CI: 1.332, 6.323 and OR = 1.990, 95% CI: 1.133, 3.494). In patients with PCOS, cumulative IVF outcomes have a positive correlation with FORT when the FORT is less than 70%. For PCOS patients with polycystic ovarian morphology, ovulation disorder or hyperandrogenic manifestations, a high FORT could be conductive to achieving better pregnancy outcomes.

Identifiants

pubmed: 36601009
doi: 10.3389/fendo.2022.1079502
pmc: PMC9806261
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1079502

Informations de copyright

Copyright © 2022 Jiang, Cao, Hao, Jia, Chen, Liu and Zhao.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2013 Apr 23;8(4):e61095
pubmed: 23637787
J Int Med Res. 2019 Oct;47(10):5146-5154
pubmed: 31379237
Am J Med. 2006 Apr;119(4):356.e1-6
pubmed: 16564785
Reprod Biomed Online. 2012 Nov;25(5):450-9
pubmed: 22999555
Hum Reprod. 2004 Sep;19(9):1936-8
pubmed: 15217998
Hum Reprod. 2021 Aug 18;36(9):2421-2428
pubmed: 34333641
Reprod Biomed Online. 2017 Jun;34(6):598-604
pubmed: 28341386
Int J Mol Sci. 2022 Mar 07;23(5):
pubmed: 35270022
Hum Reprod. 2012 Apr;27(4):1066-72
pubmed: 22279090
Hum Reprod Update. 2022 Feb 28;28(2):172-189
pubmed: 34918084
Reprod Biomed Online. 2013 Aug;27(2):147-53
pubmed: 23768619
Front Endocrinol (Lausanne). 2019 Aug 02;10:516
pubmed: 31428050
Semin Reprod Med. 2016 Mar;34(2):93-101
pubmed: 26854709
N Engl J Med. 2009 Jan 15;360(3):236-43
pubmed: 19144939
Hum Reprod. 2011 Mar;26(3):671-7
pubmed: 21177311
Transl Res. 2020 Nov;225:70-81
pubmed: 32413497
BJOG. 2007 Feb;114(2):170-86
pubmed: 17305901
Fertil Steril. 2009 Apr;91(4 Suppl):1553-5
pubmed: 19217095
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Trends Endocrinol Metab. 2017 Mar;28(3):186-198
pubmed: 27988256
Reprod Biomed Online. 2011 Jun;22(6):632-46
pubmed: 21481639
World J Diabetes. 2021 May 15;12(5):616-629
pubmed: 33995849
Fertil Steril. 2009 Mar;91(3):705-14
pubmed: 18321493
Hum Reprod Update. 2021 Apr 21;27(3):584-618
pubmed: 33302299
Gynecol Endocrinol. 2018 Jun;34(6):518-523
pubmed: 29271274
Reprod Biomed Online. 2018 Aug;37(2):163-171
pubmed: 29778554
Gynecol Endocrinol. 1987 Sep;1(3):235-45
pubmed: 3140583
Hum Reprod. 2015 Dec;30(12):2703-7
pubmed: 26466912
Ageing Res Rev. 2021 Sep;70:101378
pubmed: 34091076
Hum Reprod. 1996 Oct;11(10):2217-22
pubmed: 8943533
Fertil Steril. 2003 May;79(5):1091-100
pubmed: 12738501
J Assist Reprod Genet. 2014 Jul;31(7):829-35
pubmed: 24849376
Hum Reprod. 2010 Feb;25(2):544-51
pubmed: 19910321
Fertil Steril. 2009 Jan;91(1):148-56
pubmed: 18455166
Lancet. 1992 Jun 6;339(8806):1390-4
pubmed: 1350813
Hum Reprod Open. 2017 Aug 04;2017(2):hox011
pubmed: 31486806
J Cell Physiol. 2021 Dec;236(12):7966-7983
pubmed: 34121193
Hum Reprod. 2020 Oct 1;35(10):2272-2279
pubmed: 32951028
Med Sci Monit. 2020 Dec 11;26:e916175
pubmed: 33306667
Fertil Steril. 2010 Nov;94(6):2202-7
pubmed: 20138267
Hum Reprod. 2016 Dec;31(12):2841-2855
pubmed: 27664216
Hum Reprod. 1999 Sep;14(9):2328-32
pubmed: 10469704
Reprod Biol Endocrinol. 2011 Jan 20;9:9
pubmed: 21247501

Auteurs

Rulan Jiang (R)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Mingya Cao (M)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Haomeng Hao (H)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Rui Jia (R)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, Shenzhen Zhongshan Institute for Reproduction and Genetics, Shenzhen Zhongshan Urology Hospital, Shenzhen, China.

Peipei Chen (P)

Department of Gynecology and Obstetrics, Handan First Hospital, Handan, China.

Yuanyuan Liu (Y)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Zhiming Zhao (Z)

Department of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH